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Abstract 
Neurological diseases such as neurodegeneration, pain, psychiatric disorders, stroke and 
brain cancers would greatly benefit from the use of highly potent and specific peptide 
pharmaceuticals.  Peptides are especially desirable because of their low inherent toxicity. 
The presence of the blood-brain barrier (BBB), their short duration of action and need for 
parenteral administration limits their clinical use. However, over the last decade there have 
been significant advances in delivering peptides to the central nervous system. Angiopep 
peptides developed by Angiochem, transferrin antibodies developed by Armagen and cell 
penetrating peptides have all shown promise in delivering therapeutic peptides across the 
BBB after intravenous administration. Non-invasive methods of delivering peptides to the 
brain include the use of chitosan amphiphilie nanoparticles for oral delivery and nose to brain 
strategies. The uptake of the chitosan amphiphile nanoparticles by the gastrointestinal 
epithelium is important for oral peptide delivery.  Finally protecting peptides from plasma 
degradation is integral to the success of most of these peptide delivery strategies.  
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1.0 Introduction  
Peptides, proteins and antibodies are of increasing interest to the pharmaceutical industry 
due to their high potency and selectivity (Serrano Lopez and Lalatsa 2013).  Peptides 
biodegrade into non-toxic metabolites, possess a minimal potential for drug-drug interactions 
and are less likely to cause an immunogenic reaction when compared to larger proteins (Van 
der Walle 2011).  These favourable properties have resulted in peptides having a relatively 
good probability of securing regulatory approval, when compared to low molecular weight 
drugs (Lax 2010).  
Today the most significant impediment to translating peptides into viable therapies is their 
overwhelming need for parenteral administration and their short duration of action. Peptides, 
despite their excellent pharmacological properties, are molecules with poor physical and 
metabolic stability and peptides have a limited ability to permeate biological membranes; the 
latter due to their hydrophilicity and comparatively high molecular weight (> 500 Da).  
However, despite these limitations, the decreasing number of low molecular weight drugs 
being approved for clinical use has resulted in an intensification in efforts to find suitable 
delivery strategies for peptides; delivery strategies that would enable peptides to be 
converted into medicines.  It is interesting to note that peptides now make up 10% of the 
world’s pharmaceutical sales revenues (Reichert 2010). 
Brain diseases would benefit from the use of highly potent and specific pharmaceuticals with 
low inherent toxicity and several peptides are being investigated as therapies for 
neurological diseases, such as  neurodegeneration, pain, psychiatric disorders, stroke and 
brain cancers (Strand 2003).  These neurological diseases are responsible for more than 
12% of total global deaths (Masserini 2013). However for viable peptide neurotherapies to 
emerge, peptides need to cross the blood brain barrier (BBB) to elicit their response. The 
BBB, evolutionary designed to maintain brain homeostasis and protect the brain from 
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circulating toxins, prevents over 95% of drugs from accessing the brain (Pardridge 2005). 
Furthermore, the short plasma half life of most peptides means that virtually no peptides 
show any real brain bioavailability, unless they are transported via specific carriers.  As such 
there are currently no neuropeptide drugs on the market.  In essence the delivery of peptides 
to the brain today would require the use of extremely invasive techniques such as 
intracerebroventricular infusion, convection-enhanced delivery (Zhou, Patel et al. 2013), 
intracerebral injections, the use of intracranial implants or temporary disruption of the BBB 
by using osmotic agents, ultrasound or by the activation of the bradykinin B2 receptors 
(Gabathuler 2010).    
Nanoparticle technologies are not widely used in medicine, despite the notable exceptions 
provided by medicines such as Ambisome, Doxil and Abraxane (Uchegbu and Siew 2013). 
The complexity of nanoparticles as multi-component three dimensional constructs requiring 
careful design and engineering, detailed analytical methods and reproducible scale-up 
manufacturing processes to achieve a consistent product with the intended physicochemical, 
biological and pharmacological properties along with the lack of regulatory standards in the 
examination of nanomedicines are hindering their translation into the clinic.  However 
preclinical studies abound in which nanoparticles have shown promise in meeting the 
challenge of peptide delivery (Lalatsa, Schatzlein et al. 2012). The reasons for the use of 
nanoparticles to deliver peptides across the blood brain barrier include their small size, 
which promotes blood residence and hence brain transport of the encapsulated drug 
(Lalatsa, Lee et al. 2012; Nance, Woodworth et al. 2012), particle shape as nanofibres have 
been shown to deliver peptides across the blood brain barrier (Mazza, Notman et al. 2013) 
and the fact that nanoparticle surfaces may be decorated with various transport ligands to 
exploit a number of brain endothelial transporters such as: the low density lipoprotein (LDL) 
receptor related protein 1 & 2, and the transferrin, leptin, insulin and diphtheria toxin 
receptors (Lalatsa, Schatzlein et al. 2012; Pardridge 2012; Pardridge and Boado 2012). This 
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review focuses on recent advances in peptide brain delivery with a particular emphasis on 
the use of nanoparticle technologies.  Peptides, for the purposes of this review, are defined 
as polyamino acid bioactive agents with less than 60 amino acids.   
2.0 Pathways for the transport of peptides across the blood brain 
barrier 
There are several potential routes by which peptides could cross the blood brain barrier, 
namely by diffusion, carrier mediated uptake and receptor mediated endocytosis (Figure 1).  
For diffusion, enhanced lipophilicity is required and for receptor mediated and carrier 
mediated uptake a transport specific ligand must be incorporated within the peptide 
medicine.  
Weak hydrogen bonding potential (less than 6 hydrogen bonds), lipophilicity (Log D > 2) and 
a small molecular size (< 500 Da) along with the absence of free rotatable bonds and a polar 
surface area of < 60 - 70 Å are favourable for permeation across the BBB via diffusion 
(Pauletti, Okumu et al. 1997; Sorensen, Steenberg et al. 1997; Kelder, Grootenhuis et al. 
1999; Lennernas and Lundgren 2004). Thus, passive diffusion of natural peptides is very 
limited unless the peptides possess an amphipathic structure (Teixido, Belda et al. 2005) or 
are rendered lipophilic by synthetic means (Batrakova, Vinogradov et al. 2005; Lalatsa, Lee 
et al. 2012).   
The brain capillary endothelial cells rely upon transport proteins to facilitate the entry of 
essential polar nutrients with polarised expression on either the luminal or abluminal 
membrane (Brasnjevic, Steinbusch et al. 2009). These transport systems are specific for 
certain small peptides of no less than 10 amino acids (peroxisome Targeting Signal Type 1-
5, PTS1 - 5), hexoses (glucose transporter 1, GLUT - 1), monocarboxylic acids (Proton-
linked monocarboxylate transporter, MCT - 1), amino acids, organic anions (organic anion-
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transporting polypeptide, OATP) and organic cations (organic cation transporter novel 
subfamily, OCTN), neurotransmitters and nucleosides. Utilisation of these carrier systems 
expressed at the BBB is a useful strategy for therapeutic peptide delivery to the brain; 
however there is a need to attach specific chemical groups to the peptides in order to render 
them substrates for these endogenous carriers; e.g. the glycosylation of the peptide to 
enable transport through the GLUT - 1 receptors (Bilsky, Egleton et al. 2000; Egleton, 
Mitchell et al. 2000).  These carrier mediated strategies of peptide transport have been 
recently reviewed (Brasnjevic, Steinbusch et al. 2009; Lalatsa 2011; Lalatsa, Schatzlein et 
al. 2012) and the carrier system for glutathione (GSH), which is present at the luminal 
membrane is the only carrier mediated  system that has been used for the delivery of 
nanoparticles (Cacciatore, Baldassarre et al. 2012).  
Endocytosis is the main route of cellular entry for large molecular weight compounds and 
several peptides have been transported across the BBB via receptor mediated transcytosis 
(Brasnjevic, Steinbusch et al. 2009). Binding of the ligand to its specific membrane receptor 
on the cell surface induces a modification of the receptor protein and triggers the formation 
of invaginations; these invaginations may be clathrin coated and in turn trigger the formation 
of endocytotic vesicles (Broadwell, Balin et al. 1988). Once within the cell, the ligand 
containing vesicles can be either exocytosed leading to transport across the BBB, fused with 
a lysosome leading to intracellular degradation (Broadwell, Balin et al. 1988), or can bind to 
a second intracellular receptor as in the case of the transfer of iron from transferrin to 
intracellular ferritin (Willingham, Hanover et al. 1984).  Once there is dissociation of the 
ligand from the receptor, the receptor is recycled to the cell surface to participate in further 
transport events (Gabathuler 2010).  Another minor intracellular pathway may involve 
trafficking of endosomes, containing intact receptor ligand, to the inner saccule of the Golgi 
complex, where the enzymes can cause dissociation of the ligand from the receptor, and the 
separated ligand may then be exported in vesicles destined for lysosomal degradation 
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(Brasnjevic, Steinbusch et al. 2009). Exocytosis and the avoidance of the lysosomal pathway 
may be a special feature of the BBB compared to other types of cells and tissues, as 
transcytosis of a number of macromolecules is a homeostatic requirement (Abbott, 
Patabendige et al. 2010). Receptor-mediated endocytosis across the BBB in vivo has been 
shown for a few peptides such as insulin (Frank, Pardridge et al. 1986).  Table 1 
summarises available receptors for transport of molecules across the BBB. 
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Figure 1: Schematic diagram of the neurovascular unit forming the BBB. (Right): Routes for transport across the BBB. Modified with permission 
from (Abbott, Patabendige et al. 2010).  
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Table 1: Receptors available for transport of molecules across the BBB 
Receptor Ligand Direction Reference 
Insulin  Insulin Blood to 
Brain  
(van Houten, Posner et 
al. 1979; Frank and 
Pardridge 1981) 
Insulin like growth 
factor 
Insulin like growth factor I 
and II 
Blood to 
Brain  
(Frank, Pardridge et al. 
1986; Duffy, Pardridge et 
al. 1988) 
Transferrin Transferrin Blood to 
Brain  
(Jefferies, Brandon et al. 
1984; Fishman, Rubin et 
al. 1987; Visser, 
Stevanovic et al. 2004) 
Melanotransferrin Melanotransferrin Blood to 
Brain  
(Demeule, Poirier et al. 
2002) 
Leptin Leptin Blood to 
Brain  
(Banks and Farrell 2003) 
Tumour necrosis 
factor alpha 
Tumour necrosis factor 
alpha 
Blood to 
Brain  
(Pan and Kastin 2002) 
Epidermal growth 
factor 
Epidermal growth factor Blood to 
Brain  
(Pan and Kastin 1999) 
Immunoglobulin G Immunoglobulin G Blood to 
Brain  
(Zlokovic, Skundric et al. 
1990) 
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Receptor Ligand Direction Reference 
Interleukin Interleukin 1a, Interleukin 
1b, Interleukin 6 
Blood to 
Brain  
(Banks 2001; Banks, 
Farr et al. 2001) 
Apolipoprotein E  Lipoproteins and 
Apolipoprotein E bound 
molecules 
Blood to 
Brain  
(Herz and Marschang 
2003) 
LDL – receptor - 
related protein 1  
Lipoproteins, Amyloid - β, 
Lactoferrin 
Blood to 
Brain, Brain 
to Blood 
(Herz and Marschang 
2003) 
LDL – receptor - 
related protein 2  
Apolipoprotein E, 
Melanotransferin 
Blood to 
Brain 
(Gaillard, Brink et al. 
2005) 
Diphtheria toxin 
receptor 
Diphtheria toxin, CRM 197 
(a non - toxic mutant of the 
Diphtheria toxin) 
Blood to 
Brain 
(Gaillard, Brink et al. 
2005) 
 
The conjugation of peptide loaded nanostructures to the transport ligands shown in Table 1 
is a viable strategy for the delivery of peptides to the brain (Brasnjevic, Steinbusch et al. 
2009). However when choosing a transport ligand, the ligand should have certain properties: 
a) it should have sufficiently high affinity for the receptor and yet still enable the release of its 
cargo in the brain parenchyma, b) the endogenous ligand should not compete with the 
delivery ligand for receptor occupancy at the BBB, thus a careful consideration of the relative 
binding affinities and the physiological levels of the endogenous ligand needs to be made 
[transferrin is not a suitable ligand as its plasma concentration is >1000 fold higher than the 
12 
 
transferrin – transferrin receptor Kd (5.6 nM) (Visser, Voorwinden et al. 2004), c) the brain 
uptake of the ligand conjugate should be high enough to allow for a therapeutic dose to 
reach the brain. 
3.0 Parenteral Administration 
Due to the delivery challenges highlighted above, most experimental neuropeptides have 
been administered by parenteral routes, i.e. the intravenous route and in some preclinical 
studies via the intraperitoneal route.  Once in the blood these neuropeptides are required to 
cross the BBB.  The brain is 1% of the rodent mass and hence delivery of 1% of the injected 
dose to the brain at the peak time point, indicates a complete negation of the blood brain 
barrier in experimental studies.  However such levels are rarely achieved and morphine for 
example, a very effective CNS drug only achieves 0.02% of the dose reaching the rodent 
brain 30 minutes after subcutaneous injection  (Banks and Kastin 1994).  Hence levels of 
brain delivery in excess of 0.1% of the administered dose, represent a real crossing of the 
blood brain barrier.   A number of methods have been used to achieve brain delivery that 
can be summarised according to their reliance on endogenous transporters and the 
biological properties of the nanoparticles. 
3.1 Carrier Transport Mediated Uptake 
The glutathione carrier has been employed in delivering peptides across the BBB in the form 
of glutathione poly(ethylene glycol) (GSH-PEG) liposomes.  When these liposomes were 
loaded  with a synthetic opioid peptide (DAMGO, H –Tyr – d – Ala – Gly – MePhe – Gly - ol) 
and injected intravenously they prolonged the brain half-life of DAMGO to 6.9 ± 2.3 h, 
increasing he half life by  4.5 fold when compared to the administration of the free drug 
(Lindqvist, Rip et al. 2013).  It was found that free DAMGO entered the brain to a limited 
extent and the use of the GSH - PEG liposomes doubled the brain exposure (Lindqvist, Rip 
et al. 2013).  
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3.2 Receptor Mediated Uptake 
3.2.1 Low-density lipoprotein receptor related protein 1 (LRP1)  
A new family of 19 amino acid peptides derived from the kunitz domain of protease inhibitor 
aprotinin, and known as the Angiopeps, has been shown to facilitate transfer across the BBB 
by utilising low-density lipoprotein receptor related protein 1 (LRP - 1)  (Demeule, Currie et 
al. 2008; Demeule, Regina et al. 2008). This technology has been used to deliver both 
peptides and larger molecules such as 150 kDa antibodies (Gabathuler 2010). Angiopep – 
2’s  (TFFYGGSRGKRNNFKTEEY) positive charge contributes to its binding to the brain 
endothelial cell surface and after its interaction with LRP - 1, the Angiopep - 2 – LRP - 1 
complex is internalised by vesicle formation. LRP-1 is involved in the Angiopeps’ mechanism 
of action, and this distinguishes the Angiopeps from other positively charged peptide 
transporters such as the cell penetrating peptides (CPPs):  transcription activating factor 
(TAT), penetratin and Syn - B; these CPPs utilise adsorptive-mediated transcytosis (Herve, 
Ghinea et al. 2008; Bertrand, Currie et al. 2010). ANG2002 is a conjugate of Angiopep - 2 
peptide and neurotensin (a 13 amino acid neuropeptide). The transport of ANG2002 across 
the BBB is higher than that of unconjugated neurotensin and the conjugated neurotensin in 
ANG2002 retains its affinity for the neurotensin receptor (Demeule, Regina et al. 2010). 
Using a similar strategy, ANG2006 has been introduced and this is a conjugate of Angiopep 
-2 with Exendin - 4 (glucagon - like peptide - 1 agonist); however very limited information is 
available pertaining to this peptide conjugate (Nikolich 2009). The Angiopep technology is 
now at a clinical stage and ANG1005 (an Angiopep - 2 – paclitaxel conjugate) (Regina, 
Demeule et al. 2008; Thomas, Taskar et al. 2009; Gabathuler 2010) is currently being 
clinically evaluated for the delivery of paclitaxel to brain tumours. 
3.2.2 Low density lipoprotein receptor 
Vect-Horus S.A.S. (Marseille, France) recently identified a series of non-competitive peptide-
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based ligands for the human low density lipoprotein receptor (LDLR), e.g. VH0411, a 15 
amino acid peptide [Ac – Asp – Ser – Gly – Leu - Cys (S - bridged) – Met – Pro – Arg – Leu -
Arg – Gly – Cys (S - bridged) – Asp – Pro – Arg - NH2] (Marcor 2009). This lead compound 
led to the design of a new peptide-based vector: VH0445 (Ac - [cMet – Pro – Arg – Leu – 
Arg – Gly - Cys]c - NH2), a cyclic 8 amino acid peptide containing natural and non-natural 
amino acids (Malcor, Payrot et al. 2012). In vivo preclinical proof of principal data has been 
established in an acute pain mouse model by conjugation of VH0445 to an opioid peptide 
and an assessment of antinociceptive activity; a sharp improvement in antinociceptive 
activity was observed (Vlieghe and Khrestchatisky 2010; Vlieghe, Lisowski et al. 2010; 
Malcor, Payrot et al. 2012).  
3.2.3 Transferrin receptor 
ArmaGen Technologies have developed brain delivery technology (fusion proteins) based on 
genetic engineering of recombinant fusion proteins wherein the bioactive protein is fused to 
a molecular “Trojan horse” transporter protein. Fusion proteins have dual functions as they 
cross the BBB via one of the endogenous BBB receptor-mediated transport systems (e.g. 
the transferrin receptor) and bind neuronal or glial receptors in the brain parenchyma 
(Pardridge and Boado 2007; Pardridge and Boado 2008; Pardridge and Boado 2009; 
Pardridge and Boado 2010).  
OX26, a rat transferrin receptor monoclonal antibody, has been used to successfully target 
polymersomes and nanoparticles across the BBB. The optimal number of OX26 molecules 
conjugated to poly(ethylene glycol) - poly(epsilon - caprolactone) (PEG - PCL) 
polymersomes was found to be 34 (OX2634 - PO) and this system resulted in the delivery of  
0.14 - 0.16% of the intravenously injected dose to the brain (Pang, Lu et al. 2008). NC-1900 
(a vasopressin fragment with neuroprotective properties) was encapsulated into OX2634 - PO 
and the NC -1900 - OX2634 - PO system improved the scopolamine-induced learning and 
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reduced memory impairment in a rat water maze task after intravenous administration 
(Pang, Lu et al. 2008). Conjugation of OX26 to poly(ethylene glycol) chitosan nanoparticles 
also resulted in enhanced brain uptake after intravenous administration of an anticaspase 
peptide, Z-DEVD-FMK (Aktas, Yemisci et al. 2005).  
A peptide motif obtained from phage display experiments and with a high affinity for 
transferrin receptors (CGHKAKGPRK, denoted as B6) has also shown potential in enabling 
the permeation of poly(ethylene glycol) - poly(lactic acid) block copolymer (PEG - PLA) 
nanoparticles to the brain (Liu, Gao et al. 2013). B6 nanoparticles exhibited significantly 
enhanced cellular accumulation compared to plain PEG - PLA nanoparticles and cellular 
uptake was achieved via lipid raft-mediated and clathrin - mediated endocytosis. B6 PEG -
PLA nanoparticles were loaded with an octapeptide (NAPVSIPQ) derived from an activity 
dependent neuroprotective protein and which is being trialled clinically in Alzheimer’s 
Disease patients (Gozes, Divinski et al. 2008). Administration of B6 nanoparticles 
encapsulating the neuroprotective peptide NAPVSIPQ to Alzheimer’s disease mouse models 
resulted in excellent amelioration of learning impairments, cholinergic disruption, and a 
reduced loss of hippocampal neurons (Liu, Gao et al. 2013).  
A comparative study of nanoparticles bearing targeting ligands and their brain delivery data 
has been conducted with intravenously injected tritiated liposomes (van Rooy, Mastrobattista 
et al. 2011). Five targeting ligands were compared, namely: a) holotransferrin (a 
transmembrane glycoprotein, consisting of two linked 90 kDa subunits, that each can bind a 
transferrin molecule) (Mishra, Mahor et al. 2006; Ulbrich, Hekmatara et al. 2009), b) RI7217, 
an anti-mouse transferrin receptor monoclonal antibody (Ulbrich, Hekmatara et al. 2009), c) 
COG133, an apolipoprotein E mimetic peptide from amino acids 133 – 149 
(LRVRLASHLRKLRKRLL), e) Angiopep - 2 (Li, Sempowski et al. 2006) and f) CRM 197 (a 
non-toxic mutant of the diphtheria toxin) (Gaillard, Brink et al. 2005; Gaillard and de Boer 
16 
 
2006). Almost half of the injected dose of all the liposomes was recovered in the liver and 
spleen 12h after dosing (van Rooy, Mastrobattista et al. 2011). The COG133 peptide was 
unable to target the liposomes to the BBB. Only the anti-mouse transferrin antibody, RI7217, 
was able to improve the delivery of the liposomes to the brain. van Rooy’s data is interesting 
as in vivo brain targeting of albumin nanoparticle conjugated RI7217 had been demonstrated 
previously (Ulbrich, Hekmatara et al. 2009), but van Rooy’s study was the first report to 
demonstrate brain delivery with liposome conjugated RI7217 to the brain (0.18% of the 
injected dose was found in the brain 12 h after dosing) (van Rooy, Mastrobattista et al. 
2011).  
3.2.4 Leptin receptor 
Leptin, a 16 kDa protein produced in white peripheral adipocytes, binds to the leptin receptor 
in the choroid plexus and on the brain capillary endothelial cells, where it is taken up into the 
brain parenchyma (Banks 2001). The leptin receptor may be saturated in obese patients that 
have elevated levels of leptin (Kd of the receptor is similar to normal serum levels) 
(Burgueraa and Couceb 2001). A leptin12 - 32 fragment, g21, conjugated on the surface of 
poly(lactic - co - glycolic) acid (PLGA) nanoparticles has been shown to cross the BBB on 
intravenous injection, with 0.16% of the injected dose of nanoparticles reaching the brain 
after 2h  (Tosi, Badiali et al. 2012). No anorectic effects were seen in rats after the 
intravenous administration of 0.03 µg of the g21 transport ligand conjugated to nanoparticles 
(Tosi, Badiali et al. 2012). 
3.3 Cell Penetrating Peptides 
Cell-Penetrating Peptides (CPPs) originate from various families and are heterogeneous in 
size (10 - 27 amino acid residues) and sequence, but they all possess multiple positive 
charges at physiological pH. Some of them share common features such as an amphipathic 
sequence and the ability to interact with a lipid membrane (Morris, Deshayes et al. 2008; 
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Eiriksdottira, Konateb et al. 2010). Examples include the transcription-activating factor (TAT), 
penetratin and the SynB vectors (family of vectors derived from the antimicrobial peptide 
protegrin 1). A number of other CPPs are the product of engineering efforts, e.g. the 
homoarginine vectors, the model amphipathic peptide, transportan and other chimeric 
peptides such as signal-based peptide (SBP) and the fusion sequence-based peptide (FBP) 
(Herve, Ghinea et al. 2008).  
The TAT peptide is a non-amphipathic arginine-rich CPP derived from the TAT protein 
originating from the human immunodeficiency virus type 1 (HIV - 1), a multifunctional viral 
protein named originally for its intracellular role as a transcriptional activator of viral gene 
expression (Subrizi, Tuominenb et al. 2013). The TAT protein is actively released from 
unruptured, HIV -1 infected cells and is detectable in ex vivo culture supernatants and in the 
serum of HIV - 1 infected individuals (Subrizi, Tuominenb et al. 2013). This exogenous TAT 
is able to enter both uninfected and infected cells, however the precise molecular 
mechanism by which TAT enters the cells is still unclear. TAT binds to cell-surface heparin 
sulphate and the binding of the full - length TAT protein to both heparin sulphate 
proteoglycans and the low - density lipoprotein receptor family has been confirmed (Rusnati, 
Coltrini et al. 1997; Liu, Jones et al. 2000). The basic domain of TAT extending from 
residues 49 to 58 (RKKRRQRRR) includes a highly cationic cluster composed of 6 arginine 
and 2 lysine residues that play an important role in the translocation of the protein across 
biological membranes; translocation is aided by the strong cell adherence of this motif and 
cell binding is independent of cell receptors and of temperature (Subrizi, Tuominenb et al. 
2013). The guanidinium head group of arginine is required for peptide uptake and is more 
potent than other cationic groups, such as lysine, histidine or ornithine (Mitchell, Steinman et 
al. 2000). The mechanism of cellular penetration, which is often compared to a Trojan horse 
approach, involves two distinct steps: endocytic uptake followed by endosomal escape 
(Erazo-Oliveras, Muthukrishnan et al. 2012).  
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Memapsin - 2 (β-secretase or BACE) inhibitors are particularly attractive candidates for 
Amyloid β reduction therapy since β - secretase cleavage of amyloid precursor protein 
represents the initial step in the biogenesis of Amyloid β. It is hypothesised that the inhibition 
of this step would lead to the elimination of all steps in the pathogenesis of Alzheimer’s 
disease, but memapsin - 2 inhibitors are not able to permeate the BBB. Conjugation of a 12 
residue TAT fragment but preferably a 9-residue poly – D - Arginine to a peptide analogue 
inhibitor of memapsin (Wender, Mitchell et al. 2000) resulted in a 64% reduction of Amyloid 
β levels after a single intraperitoneal injection (Chang, Koelsch et al. 2004). Multiple 
injections to simulate a longer half life of the inhibitor produced maximal inhibition of about 
90% in the plasma and about 70% in the brain (Chang, Koelsch et al. 2004). 
Nanoparticulate drug delivery system possesses distinct advantages for brain drug delivery. 
However, their permeation across the BBB is not always therapeutically adequate. Cell-
penetrating peptides (CPPs), short peptides that facilitate cellular uptake of various 
molecular cargoes, would be appropriate candidates for facilitating brain delivery of 
nanoparticles encapsulating peptides. Examples of the use of CPPs to deliver nanoparticles 
across the BBB are given below 
The SynB peptides (RGGRLSYSRRRFSTSTGR) are a family of cell-penetrating peptides 
that show charge - mediated BBB selectivity, with uptake proceeding via a caveolae-
independent pathway (Drin, Cottin et al. 2003). The SynB peptide family is derived from the 
natural antimicrobial peptide protegrin 1 (PG - 1) originally isolated from porcine leukocytes. 
PG -1 is an 18 amino acid long peptide with an antiparallel beta-sheet structure stabilized by 
two disulﬁde bridges. It interacts with, and forms pores in the lipid matrix of bacterial 
membranes. Various linear analogues of PG -1 that lack cysteine residues have been 
designed and these are devoid of the membrane-disrupting activity of PG -1 (Harwig, Waring 
et al. 1996; Mangoni, Aumelas et al. 1996; Chen, Falla et al. 2000).  
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SynB peptides have been used extensively as cationic cell penetrating peptides for low 
molecular weight actives (Adenot, Merida et al. 2007) and for peptides such as dalargin 
(Rousselle, Clair et al. 2003); with transport observed across cell membranes in vitro and 
across the BBB in vivo when administered intravenously.  There have also been recent 
reports of the use of SynB peptides as brain transport systems for nanoparticles.  For 
example, intravenously injected SynB pegylated gelatin siloxane nanoparticle (SynB – PEG - 
GS) levels in the brain were significantly higher and levels in the liver significantly lower 
compared to plain nanoparticles (Tian, Wei et al. 2012). 
Penetratin, a CPP with a relatively low content of basic amino acids, has been used to 
functionalize poly(ethylene glycol)-block-poly(lactic acid) (PEG - PLA) nanoparticles and 
penetratin enhanced the cellular accumulation (Xia, Gao et al. 2012). In vivo 
pharmacokinetic and biodistribution studies showed that penetratin nanoparticles exhibited 
significantly enhanced brain uptake and reduced accumulation in the non-target tissues 
compared with low molecular weight protamine (a CPP with high arginine content) 
functionalized nanoparticles (Xia, Gao et al. 2012).  
A thermally responsive elastin like polypeptide (ELP) covalently attached to a cell-
penetrating peptide and a therapeutic inhibitory peptide (inhibits the oncogenic c - Myc 
protein) has been shown to be able to enhance delivery to rat brain tumours and mediate 
uptake across the tumour cells’ plasma membranes on intravenous administration (Table 1) 
(Bidwell, Perkins et al. 2013). Specifically, when the lead CPP – ELP - fused c - Myc inhibitor 
was combined with focused hyperthermia of the tumours, an 8 fold increase in tumour 
polypeptide levels was observed.  Additionally an 80% reduction in tumour volume was 
recorded along with a delayed onset of tumour-associated neurological deficits, a doubling of 
the median survival time and complete tumour regression in 80% of the animals (Bidwell, 
Perkins et al. 2013).  
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The ability of CPPs to penetrate many cell types in vitro, as well as in vivo greatly restricts 
their application as pharmaceutical tools and hence methods of targeting CPPs are being 
investigated. Such strategies may exploit specific cell features, such as extracellular 
receptors or enzymes, or use of small or large cell-binding ligands (e.g. vitamins, growth 
factors or antibodies) which, when incorporated into CPPs, may render these cationic 
peptides capable of distinguishing between non-target and target cells (Herve, Ghinea et al. 
2008). The stability of peptide vectors is an important factor regarding their use for in vivo 
delivery, as the vector must not be metabolically cleaved until it delivers its cargo to the 
appropriate target. In studies, transportan (GWTLNSAGYLLGKINLKALAALAKKIL amide), its 
analogue transportan 10 (TP10, AGYLLGKINLKALAALAKKIL amide) and TAT (47-57) 
(YGRKKRRQRRR) were shown to be more stable than penetratin 
(RQIKIWFQNRRMKWKK) for example (Herve, Ghinea et al. 2008). The use of D-amino 
acids is one way to enhance the stability of these transport peptides. However, it is critical 
that when the vector reaches its target it should subsequently degrade or release its cargo in 
order to elicit its pharmacological response. Toxicity and immunogenicity are also important 
issues to be considered when translating these brain delivery strategies to the clinic. The full 
- length TAT protein produced lower levels of neurotoxicity than the shorter peptides TAT (31 
- 71) and TAT (31 - 61) in that order (Herve, Ghinea et al. 2008). Both the cysteine - rich 
domain extending from residues 32 to 47 and the basic domain (positions 48 – 57) seem to 
be essential for neurotoxicity to develop (Herve, Ghinea et al. 2008). The assessment of the 
toxicity of unmodified CPPs using a lactate dehydrogenase (LDH)-leakage, DiBAC4(3) - 
(membrane depolarization), and hemolytic assay showed rather severe toxic effects of 
transportan 10 as representative of the amphipathic CPPs, but it showed only mild effects of 
the arginine - rich peptides TAT and penetratin (Tünnemann and Cardoso 2009). However, 
the toxicological properties can be dramatically changed on attachment of low-molecular-
weight cargoes, for example, labels or other peptides (Tünnemann and Cardoso 2009). 
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Finally, as CPPs are derived from non-human proteins and since, in the case of 
administration to humans, these peptides have the potential to induce an immune response; 
one must consider that this risk of an immune response  may increase considerably if these 
vectors are conjugated to particularly large peptide molecules.  
3.4 Passive Delivery 
3.4.1 Polymeric Nanoparticles: 
Peptide brain delivery may also be achieved by using a polymeric or lipid nanocarrier loaded 
with a hydrophilic peptide. Various examples of such strategies have been reported and the 
majority of these approaches are exemplified with analgesic peptides (Table 2) (Aliautdin, 
Petrov et al. 1996; Lalatsa, Garrett et al. 2012; Lalatsa, Lee et al. 2012). Nanomerics Ltd (St 
Albans, U. K.), for example, is exploiting technology based on an engineered amphiphilic 
chitosan polymer (Quaternary ammonium palmitoyl glycol chitosan - GCPQ) tailored to form 
nanoscale polymeric aggregates that are able to package or specifically interact with 
peptides. Preclinically the technology has been successful in delivering leucine5 - enkephalin 
(an endogenous opioid peptide with a plasma half-life of 3 minutes) across the BBB, with 
anti-nociceptive activity demonstrated in a rodent acute pain animal model after both 
intravenous (Lalatsa, Garrett et al. 2012) and oral administration (Lalatsa, Garrett et al. 
2012) (Table 2). The anti - nociceptive response in these studies lasted for up to 8 hours.  
The ability to elicit a short lived pharmacological effect (30 minutes and 90 minutes) after the 
administration of dalargin (a mu opioid receptor agonist peptide) loaded poly(butyl 
cyanoacrylate) nanoparticles coated with either  polysorbate 80 or poly(ethylene glycol) 
(molecular weight = 20 kDa) via the intravenous and oral route respectively has also been 
shown (Schroeder, Sommerfeld et al. 1998; Das and Lin 2005). A polysorbate 80 coating of 
the poly(butyl cyanoacrylate) nanoparticles was critical for dalargin entry into the brain as 
this coating enables the particles to adsorb Apolipoprotein E from the blood plasma onto the 
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nanoparticle surface and it is this Apolipoprotein E coating that is believed to facilitate 
transport across the BBB via the LDL – receptor (Kreuter, Shamenkov et al. 2002).   
Vesicles prepared from bolaamphiphiles containing two hydrophilic head groups at each end 
of a hydrophobic lipidic chain have been used to enhance permeation of small hydrophilic 
analgesic peptides across the BBB and are characterised by high chemical and physical 
stability and the ability to be destabilised by esterases leading to changes in the head 
groups; such head group changes disrupt the vesicular structure and release the 
encapsulated peptide in tissues with high acetylcholinesterase activity such as the brain 
(Popov, Abu Hammad et al. 2013). The presence of chitosan pendant groups appears to 
enhance antinociception elicited with these bolaamphiphilic vesicles (Table 2).  
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Table 2: Peptide delivery across the BBB  
Strategy Peptide Develop-
mental Stage 
- Route 
Therapeutic advantage References 
Passive Delivery 
Polymeric Nanoparticles 
Quaternary 
ammonium 
palmitoyl glycol 
chitosan (GCPQ) 
nanoparticles 
Leucine
5 
-
enkephalin, 
Tyrosyl
1
 
Palmitate-
Leucine
5 
-
enkephalin 
(Lipidised 
prodrug of 
Leucine
5 
-
enkephalin) 
Preclinical – 
Intravenous, 
Oral 
A sustained anti-
nociceptive effect on 
intravenous and oral 
administration and 
enhanced levels of 
leucine
5 
- enkephalin are 
detected in the brain.   
Leucine
5 
- enkephalin 
alone is inactive. 
(Lalatsa, 
Garrett et al. 
2012; 
Lalatsa, 
Garrett et al. 
2012) 
Poly(butyl 
cyanoacrylate ) 
nanoparticles 
coated with 
polysorbate - 80  
Dalargin 
 
Preclinical - 
Intravenous 
Enhanced antinociception. (Schroeder, 
Sommerfeld 
et al. 1998) 
 
 
Bolaamphiphiles 
Bolaamphiphile 
vesicles 
Leucine
5 
-
enkephalin 
Preclinical - 
Intravenous 
Vesicles produced using 
GLH -19 and GLH - 20 
(Popov, Abu 
Hammad et 
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Strategy Peptide Develop-
mental Stage 
- Route 
Therapeutic advantage References 
(prepared from 
GLH - 19, GLH - 
20, or a mixture of 
GLH - 19 and GLH 
- 20, with and 
without chitosan 
pendant groups) 
bolalipids loaded leucine
5 
-
enkephalin produced 
enhanced antinociceptive 
effects upon intravenous 
administration, particularly 
when the bolaamphiphiles 
loaded with leucine
5 
-
enkephalin contained 
chitosan pendant groups.  
al. 2013) 
Peptide Amphiphiles 
Nanofibers O - palmitoyl 
tyrosinate 
ester
1‐dalargin 
Preclinical - 
Intravenous 
Prolonged antinociceptive 
response. Dalargin alone 
is inactive. 
(Mazza, 
Notman et al. 
2013)  
Amphiphilic 
peptide core - 
shell 
nanoparticles 
Amphiphilic 
peptide 
(CGGGRRRRR
RTAT) 
Preclinical - 
Intravenous 
Enhanced antimicrobial 
activity in a 
Staphylococcus aureus in 
vivo meningitis model in 
rabbits (two intravenous 
doses) 
(Liu, Xu et al. 
2009) 
Actively targeted nanoparticles 
Glutathione 
Poly(ethylene 
DAMGO (H –Tyr 
– d – Ala – Gly – 
Preclinical -
Intravenous 
Enhancement of plasma 
half life and doubling of 
(Lindqvist, 
Rip et al. 
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Strategy Peptide Develop-
mental Stage 
- Route 
Therapeutic advantage References 
glycol) liposomes 
(GSH - PEG 
liposomes) 
MePhe – Gly - 
ol) 
brain exposure of DAMGO 
when administered as a 
GSH - PEG liposomal 
formulation 
2013) 
OX26 – 
poly(ethylene 
glycol) – block - 
poly (epsilon 
caprolactone)  
(PEG - PCL) 
polymersomes 
NC1900 (a 
vasopressin 
fragment) 
Preclinical - 
Intravenous 
Improved the scopolamine 
- induced learning and 
memory impairments in a 
water maze task after 
intravenous administration 
in rats 
(Pang, Lu et 
al. 2008) 
OX26 
poly(ethylene 
glycol) chitosan 
nanoparticles  
Z-DEVD-FMK (a 
specific caspase 
inhibitor) 
Preclinical - 
Intravenous 
Enhanced brain 
translocation after 
intravenous administration 
in Swiss albino mice 
(Aktas, 
Yemisci et al. 
2005) 
Lactoferrin PEG – 
PCL 
nanoparticles 
NAPVSIPQ  Preclinical -
Intranasal 
Administration lactoferrin 
PEG - PCL nanoparticles 
loaded with NAPVSIPQ 
improved behaviour in a 
Morris water maze 
experiment when 
compared to NAPVSIPQ 
PEG - PCL nanoparticles 
(Liu, Jiang et 
al. 2013) 
26 
 
Strategy Peptide Develop-
mental Stage 
- Route 
Therapeutic advantage References 
alone. 
Angiopep - 2  
Neurotensin 
(ANG2002)  
Neurotensin Preclinical - 
Intravenous 
Enhancement of the foot 
licking latency in a mouse 
hot plate assay, reduced 
licking responses in 
formalin - induced pain 
model and reduced 
mechanical allodynia in 
both  a Brennan post-
operative pain model and 
a Chung model for 
neuropathic pain 
(Demeule, 
Regina et al. 
2010) 
VH0445 peptide 
conjugates 
Opioid peptide Preclinical - 
Intravenous 
Enhancement of 
antinociceptive activity in 
mice 
(Vlieghe and 
Khrestchatis
ky 2010; 
Vlieghe, 
Lisowski et 
al. 2010; 
Malcor, 
Payrot et al. 
2012) 
Cell Penetrating Peptide Conjugates   
Cell penetrating c - Myc Preclinical - Combining CPP - ELP (Bidwell, 
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Strategy Peptide Develop-
mental Stage 
- Route 
Therapeutic advantage References 
peptide – elastin 
like polypeptide 
fused to c - Myc 
inhibitory peptide 
inhibitory 
peptide  
Intravenous fused c - Myc inhibitor with 
focused hyperthermia of 
the tumours, resulted in an 
80% reduction in tumour 
volume, delayed onset of 
tumour-associated 
neurological deficits, and a 
doubling of the median 
survival time.  There was 
also complete tumour 
regression in 80% of 
animals. 
Perkins et al. 
2013) 
TAT- NBD peptide NBD (anti – NF-
κB peptide) 
Preclinical -
Intanasal 
Delivery of 1.4 mg kg 
-1
 
TAT - NBD, markedly 
attenuates NF-κB 
signalling, microglia 
activation, and brain 
damage triggered by 
hypoxic ischemia  
(Yang, Sun 
et al. 2013) 
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Strategy Peptide Develop-
mental Stage 
- Route 
Therapeutic advantage References 
9 - residue poly –
D - Arginine – 
Memapsin - 2 
Memapsin - 2 (β 
- secretase 
inhibitor) 
Preclinical -
Intraperitoneal 
Multiple injections 
produced a maximal 
reduction in Amyloid β 
levels (a reduction of 90% 
in the plasma and 70% in 
the brain) in transgenic 
Tg2576 mice 
(Chang, 
Koelsch et 
al. 2004) 
SynB - Dalargin Dalargin Preclinical – 
Intravenous  
Enhancement of 
antinociception of Dalargin 
in a hot-plate murine 
model 
(Rousselle, 
Clair et al. 
2003) 
Key; c-Myc: oncogenic protein expressed in 78% of human glioblastoma multiforme tumours, GLH-
19: Acetyl choline head groups attached via the oxygen atoms to vernonia oil derivatives, GLH-20: 
Acetyl choline head groups attached via the nitrogen atoms to vernonia oil derivatives, NAPVSIPQ: 
Asparagine-Alanine-Proline-Valine-Serine-Isoleucine-Proline-Glutamine, NC 1900: Vasopressin 
fragment, NGF: Nerve growth factor, OX26:  anti-transferrin receptor antibody IgG2a, TAT peptide: 
Tyrsoine-Glycine-Arginine-Lysine-Lysine-Lysine-Arginine-Arginine-Glutamine-Arginine-Arginine-
Arginine, TAT-NBD: 22 amino-acid CPP containing the NF - κB Essential Modulator (NEMO)/IKKγ - 
Binding Domain coupled to the transduction sequence of the HIV - TAT protein, VH0445: Ac -[cMet -
Pro-Arg-Leu-Arg-Gly-Cys]c-NH2), a cyclic 8-mer peptide with enhanced permeation across the blood-
spinal cord barrier.  
 
3.4.2 Peptide amphiphiles 
Peptides can molecularly arrange into a variety of structures mediated by hydrogen bonding, 
electrostatic interactions particularly between charged amino acids, hydrophobic 
associations and π – π stacking (Ulijn and Smith 2008). Amphipathic peptides possess both 
hydrophobic and hydrophilic parts and they can be natural peptides (as with penetratin for 
example), engineered by inclusion of hydrophobic and hydrophilic amino acid mini blocks or 
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by point lipidisation of specific amino acid residues, e.g. by conjugation for example of a 
hydrophobic alkyl or acyl chain. The distinct separation between the hydrophilic and 
hydrophobic parts of the molecule drives self-assembly in aqueous environments and the 
net result is the formation of spherical (Zhang, Marini et al. 2002), membrane (Zhang, 
Holmes et al. 1993), hydrogel (Zhang, Marini et al. 2002) or fibrous aggregates (Zhang, 
Marini et al. 2002; Mazza, Notman et al. 2013). Peptide micellar aggregates and nanofibres 
have been successfully used to deliver peptides across the BBB.  
Peptide nanofibres are typically prepared by probe sonication of an aqueous dispersion of 
the peptide amphiphile. Peptide nanofibres consist of a central hydrophobic core surrounded 
by a β - sheet of peptides (Paramonov, Jun et al. 2006) with the peptide β - sheet wrapped 
tightly around the hydrocarbon core (Mazza, Notman et al. 2013) and the cylindrical 
assembly primarily driven by the β - sheet. The presence of a β - sheet forming peptide 
sequence, a charged amino acid and an alkyl chain linked to one end of the peptide have 
been proposed as critical parameters important for engineering peptide nanofibres (Cui, 
Webber et al. 2010). Our group was the first to show that therapeutic peptides could be 
made to assemble into peptide nanofibres, with the report that the acyl derivatised 
therapeutic peptide, namely O - palmitoyl tyrosinate ester1 ‐ dalargin self assembles into 
nanofibres (Mazza, Notman et al. 2013).  These nanofibres cross the BBB and produce a 
pharmacological response on intravenous administration; whereas the peptide dalargin 
alone is inactive via this route (Mazza, Notman et al. 2013).  Furthermore peptide nanofibres 
in which the peptide does not contain a charged amino acid have been produced from O-
palmitoyl tyrosinate ester1 ‐ leucine5 ‐ enkephalin and this molecule also is active via the 
intravenous route, where again the peptide alone is inactive.  These peptide nanofibres act 
as a self assembled prodrug, releasing the drug itself from its ester linkage in vivo ((Lalatsa, 
Schatzlein et al. 2013; Mazza, Notman et al. 2013). A passive mechanism of transport for 
the peptide nanofibers is envisaged due to the increased lipophilicity of the peptide 
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amphiphiles, but the mechanism of transport has not yet been fully elucidated. Peptide 
nanofibres are a promising delivery strategy for the transport of peptides across the BBB.  
Amphiphilic engineered peptides (CGGGRRRRRRTAT) able to form core-shell 
nanoparticles also demonstrate enhanced antimicrobial activity in a Staphylococcus aureus 
in vivo meningitis model. Peptide amphiphile spherical aggregates have been prepared by 
incubation of the peptide amphiphile in aqueous media at 35 °C for 24 hours (Liu, Xu et al. 
2009).  
4.0 Oral Administration 
Technologies able to ensure non-invasive delivery of peptide and protein therapies to the 
brain hold immense commercial potential. The oral and the intranasal route are the only 
routes that have shown some promise in this respect. The low bioavailability of peptides via 
the oral route which is a direct result of their physical and enzymatic instability and their low 
permeability across biological membranes may be overcome by the use of nanoparticle 
technologies (Serrano Lopez and Lalatsa 2013). The pharmaceutical industry, driven by the 
medical and clinical success of intravenously administered biologics is increasingly 
investigating more complex brain peptide delivery systems in order to enter niche treatment 
markets and address the growing need for brain therapeutics. An oral to brain peptide 
delivery technology may provide an answer to a therapeutic field with unmet needs in the 
form of drugs to treat an ever growing catalogue of neurological diseases 
(neurodegeneration, pain and cancer for example). 
Nanoparticle technologies are the only strategies able to protect peptides in the harsh 
environment of the gastrointestinal tract, enhance their absorption across the gastrointestinal 
mucosa and increase their circulation half life in order to maintain an adequate concentration 
of peptide in the plasma for transport across the BBB. Oral to brain peptide delivery, has 
been demonstrated with opioid peptide analgesics. The first reported strategy able to deliver 
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peptides orally involved the analgesic peptide dalargin, encapsulated in 
poly(butylcyanoacrylate) nanoparticles coated with either polysorbate 80 (Schroeder, 
Sommerfeld et al. 1998) or polyethylene glycol (molecular weight = 20 kDa) (Das and Lin 
2005). However, although the intellectual property protection was secured for this technology 
over 15 years ago (Sabel B. A. and U. 1997), the technology appears not to have 
progressed beyond the preclinical stage. 
Nanomerics Ltd (St Albans, U. K.) 
has shown that its proprietary 
Molecular Envelope Technology 
(MET) – quaternary ammonium 
palmitoyl glycol chitosan (GCPQ) 
nanoparticles achieves the oral 
delivery of peptides and lipophilic 
peptide prodrugs to the brain 
(Lalatsa, Garrett et al. 2012; 
Lalatsa, Lee et al. 2012).  The 
technology works by protecting the 
peptide from degradation in the 
gut, the nanoparticles being taken 
up by the enterocytes, the 
absorbed particles stabilising the 
peptide and peptide prodrug 
against plasma degradation and 
the particles adhering to the 
endothelial cells of the blood brain 
 
Figure 2a: Brain levels showing the oral to brain 
delivery of leucine5-enkephalin (70 mg kg−1, ) and 
a lipidised leucine5-enkephalin prodrug (O-tyrosinyl 
palmitate leucine5-enkephalin, 100 mg kg−1, ) 
encapsulated in Nanomerics Molecular Envelope 
Technology (GCPQ Nanoparticles).  Brain levels of 
leucine5-enkephalin alone () are also shown. 
Figure 2b: The anti-nociceptive response following 
the oral administration of leucine5-enkephalin and 
O-tyrosinyl palmitate leucine5-enkephalin 
encapsulated in Nanomerics Molecular Envelope 
Technology. Symbols are as in Figure 2a.  A group 
of mice were also dosed with water (▲).  The drug, 
GCPQ ratio was 1: 5 g g-1. Reproduced with 
permission from reference (Lalatsa, Lee et al. 2012). 
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barrier, enabling the peptide and the peptide prodrug to cross the BBB (Figure 2) by as yet 
unclear cellular mechanisms (Garrett, Lalatsa et al. 2012; Lalatsa, Garrett et al. 2012; Siew, 
Le et al. 2012).  In the case of formulations comprised of the prodrug, the drug is released 
from the prodrug by plasma, liver and possibly brain esterases (Lalatsa, Lee et al. 2012).  
Developing medicines from endogenous peptides does not require validation of the 
mechanism of action for the active therapeutic.  This is critical if one wishes to avoid the high 
attrition rates in late clinical development as clinical proof-of concept data is already 
available. Although commercialisation of peptides as oral therapies is still deemed risky by 
the pharmaceutical industry, the rewards of niche treatment areas should fuel the 
development of peptide pill technologies by smaller market entrants. 
5.0 Intranasal Administration 
Nasal delivery is a promising alternative to intravenous injection for the delivery of peptides 
and proteins as the large surface area and high vascularity of the nasal cavity favours fast 
absorption of therapeutic molecules into the systemic circulation. However, peptide 
intranasal bioavailability is considerably less effective than after intravenous administration 
due to enzymatic degradation or mucociliary clearance, and poor mucosal membrane 
permeability of large polar substrates (Irwin, Dwivedi et al. 1994).  
Exploitation of the nasal route for the delivery of drugs to the brain via the olfactory region 
has been explored as the olfactory region of the nose can be a major site for entry of viruses 
into the brain (Illum 2000; Reis, Veiga et al. 2008). In order for a peptide to travel from the 
olfactory region in the nasal cavity to the cerebrospinal fluid (CSF) or the brain parenchyma, 
it has to traverse the nasal olfactory epithelium and, depending on the pathway followed, 
also the arachnoid membrane surrounding the subarachnoid space.  Three different 
pathways across the olfactory epithelium may be envisaged; a) a transcellular pathway, 
especially across the sustentacular cells, most likely by receptor mediated endocytosis, fluid 
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phase endocytosis or by passive diffusion (unlikely for peptides), b) a paracellular pathway 
through tight junctions between the sustentacular cells and olfactory neurones and c) via the 
olfactory nerve pathway where the drug is taken up into the neurons by endocytotic or 
pinocytotic mechanisms and transported by intracellular axonal transport to the olfactory 
bulb (Illum 2000). The transneuronal pathway is very slow and agents reach the CNS as late 
as 24 hours after administration, hence transport via neuronal routes cannot explain the 
rapid appearance of drug in the CSF that is seen for a range of low molecular weight 
compounds (Illum 2000).  Hence, at least in animal models, a therapeutic molecule with 
moderate lipophilicity, i.e. one that is not so lipophilic so as to give rapid transport into the 
systemic circulation, will show a higher CSF and olfactory bulb concentration after nasal 
administration than after parenteral administration (Illum 2000). 
Leucine5 - enkephalin loaded N - trimethyl chitosan nanoparticles prepared using the ionic 
gelation method were evaluated as a brain delivery vehicle via the nasal route. Using the N -
trimethyl chitosan gel nanoparticles, there was significant improvement in the observed 
antinociceptive effect of leucine5 - enkephalin, as evidenced by the hot plate and acetic acid 
induced writhing bioassay (Kumar, Pandey et al. 2013). Polysorbate 80 coated nanoparticles 
loaded with neurotoxin II (an analgesic peptide which was separated from the venom of Naja 
atra) also resulted in enhanced antinociception after intranasal delivery (Ruan, Yao et al. 
2012).  
Thyrotropin-releasing hormone (TRH) is reported to have anticonvulsant effects in epileptic 
patients but is unable to cross the BBB and is rapidly metabolised in the periphery.  The 
intranasal administration of TRH loaded poly (D,L - lactic acid) nanoparticles reduced the 
frequency and severity of seizures in a rat seizure model. (Kubek, Domb et al. 2009; 
Veronesi, Aldouby et al. 2009).   
Coating particles with brain endothelial cell transport ligands has also been explored via the 
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intranasal route.  Lactoferrin, a natural 80 kDa iron binding cationic glycoprotein of the 
transferrin family, consists of a single-chain glycoprotein folded into two globular lobes and 
lactoferrin is expressed in various tissues and involved in various physiological processes, 
such as iron uptake by the intestinal mucosa and acting as a bacteriostatic agent (Lönnerdal 
and Iyer 1995; Suzuki, Lopez et al. 2005). Extensive histological studies revealed that the 
lactoferrin receptor is highly expressed in brain endothelial cells and neurons and 
overexpressed in the CNS in  age-related neurodegenerative diseases including Alzheimer’s 
Disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (Liu, 
Jiang et al. 2013). Furthermore, lactoferrin is more efficiently taken up by the brain tissue 
than both transferrin and OX26 (Ji, Maeda et al. 2006). The intranasal administration 
lactoferrin conjugated poly(ethylene glycol) – block - poly(epsilon caprolactone) (PEG - PCL) 
nanoparticles loaded with the neuroprotective peptide NAPVSIPQ produced superior results 
to NAPVSIPQ loaded onto plain PEG - PCL nanoparticles.  Pharmacological activity was 
evaluated in a rat Morris water maze experiment (Liu, Jiang et al. 2013).  The behavioural 
pharmacodynamic activity improvements were supported by the evaluation of 
acetylcholinesterase activity, choline acetyltransferase activity and neuronal degeneration in 
the mice hippocampus (Liu, Jiang et al. 2013).  
Another successful nasal strategy involved PEG - PLA nanoparticles modified with wheat 
germ agglutinin loaded with vasoactive intestinal peptide.  This formulation resulted in 
enhanced brain uptake and improvements in spatial memory in ethylcholine aziridium -
treated rats following the intranasal administration of 25 g kg-1 and 12.5 g kg-1 of 
vasoactive intestinal peptide loaded on unmodified nanoparticles and wheat germ agglutinin-
modified nanoparticles, respectively (Gao, Wu et al. 2007). An intranasal peptide delivery 
system was also developed by conjugation of odorranalectin (MW = 1700 Da, a leptin like 
peptide) to cubosomes via a non-covalent streptavidin - biotin "bridge".  Odorranalectin 
retained its bio - recognitive activity and enhanced the nose to brain delivery of 
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Gly14Humanin (a neuroprotective peptide) (Wu, Li et al. 2012).  Pharmacodynamics effects 
were measured in a Morris water maze test and by acetylcholinesterase activity (Wu, Li et al. 
2012).   
TAT peptides have also been utilised via the intranasal route.  TAT-NBD, a 22 amino-acid 
CPP containing the nuclear factor kappa B (NF - κB) IKKγ - Binding Domain coupled to the 
transduction sequence of the HIV - TAT protein, is a potent NF- κB inhibitor that attenuates 
inflammatory responses  (Yang, Sun et al. 2013). Yet, intravenous delivery of TAT - NBD 
peptides still requires a high dose to cross the BBB to reach the central nervous system; 
such a high dose may weaken general immunity and increase the risk of severe infection 
(Yang, Sun et al. 2013). In an attempt to reduce the required dose, intranasal delivery of 
TAT - NBD peptides was carried out in two animal models of neonatal infection sensitised 
hypoxic-ischemic brain injury. Kinetic experiments showed that TAT - NBD peptides entered 
the olfactory bulbs rapidly (within 10 – 30 min) and peaked in the cerebral cortex around 60 
min after the intranasal application in P7 rats (Yang, Sun et al. 2013). Further, intranasal 
delivery of 1.4 mg kg-1 TAT - NBD, which is only 7% of the intravenous dose, markedly 
attenuated NF- κB signalling, microglia activation, and the brain damage triggered by 
hypoxic ischemia (following a 4 or 72 h exposure to the bacterial endotoxin 
lipopolysaccharide) (Yang, Sun et al. 2013). 
Intranasal to the brain peptide delivery strategies have not only been the subject of 
preclinical experiments but have been exploited in clinical studies and even resulted in the 
launch of peptide products. Peptides such as melanocortin (4-10), angiotensin II, arginine-
vasopressin, cholecystokinin - 8, oxytocin and insulin have been successfully delivered to 
the brain in human trials (Table 2). However, recently Allon Therapeutics Inc. announced 
that its drug candidate davunetide [NAP, eight amino acid peptide (NAPVSIPQ)] failed to 
show efficacy for progressive supranuclear palsy (PSP) in a phase 2/3 trial. Participants 
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showed no benefit on either of the primary outcome measures, the progressive supranuclear 
palsy rating scale and the Schwab and England Activities of Daily Living and neither 
secondary endpoints either (ClinicaSpace 2012).  
Table 3 Summary of clinical studies of nasal delivery of peptides to CNS  
Peptide Molecular 
Weight (Da) 
Pharmacokinetics Pharmacodynamics References 
Melanocortin (4 -
10) 
980 Detected in CSF Acutely diminished 
focusing of attention, 
decreased body - fat in 
normal weight humans 
(Born, Lange et 
al. 2002), (Fehm, 
Smolink et al. 
2001), (Smolnik, 
Perras et al. 
2000), 
(Hallschmid, 
Smolnik et al. 
2006) 
Angiotensin II 1084 Not determined Acutely increased blood 
pressure  
(Derad, Willeke 
et al. 1998) 
Arginine – 
vasopressin 
1046 Detected in CSF Enhanced brain activity (Pietrowsky, 
Struben et al. 
1996) 
Cholecystokinin - 
8 
1143 Not determined Enhanced brain activity (Pietrowsky, 
Thiemann et al. 
1996) 
Oxytocin 1007 Not determined Increased trust, reduce 
stress-related control, 
(Kosfeld, 
Heinrichs et al. 
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produced anxiolytic 
effects, attenuated 
response to fear in 
amygdala in 
generalised anxiety 
disorder, improved 
emotional recognition in 
autism 
2005), (Kirsch, 
Esslinger et al. 
2005), (Domes, 
Heinrichs et al. 
2007), (Heinrichs, 
Baurngartner et 
al. 2003), 
(Labuschange, 
Phan et al. 2010), 
(Guastella, 
Einfeld et al. 
2010) 
Insulin 5808 Detected in CSF Reduced brain activity, 
decreased food intake, 
enhanced postprandial 
thermogenesis, 
improved memory and 
modulated Ab in 
patients with mild 
cognitive impairment 
(Kern, Born et al. 
1999), (Benedict, 
Hallschmid et al. 
2004), (Benedict, 
Kern et al. 2008), 
(Benedict, Brede 
et al. 2011), 
(Reger, Watson 
et al. 2008) 
 
 
6.0 Concluding Remarks 
Over the last decade there have been significant advances in the delivery of peptides, to the 
brain. Various vectors have been shown to deliver peptides across the BBB with notable 
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promise offered by receptor mediated endocytosis strategies such as the Angiopep peptides 
pioneered by Angiochem and transferrin antibodies developed by Armagen.  The chitosan 
amphiphile nanoparticles developed by Nanomerics, cell penetrating peptides and the 
utilisation of nose to brain strategies by a number of companies are also recording notable 
successes.  Protecting intravenous peptides from plasma degradation is a key to achieving 
brain delivery of these molecules on intravenous administration.  With respect to the oral 
route, data has been presented on the oral delivery of peptides to the brain by utilising 
chitosan amphiphile nanoparticles that are taken up by the gastrointestinal epithelium.  
Controlling neurological conditions will continue to be at the forefront of therapeutic 
strategies for the foreseeable future.  The possibility of delivering medicines containing drug 
compounds that do not usually distribute to the brain, by using the technologies and 
approaches described above, means that new medicines will emerge to tackle these rather 
challenging conditions.     
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